Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus

Transplantation

Volumn 88, Issue 1, 2009, Pages 69-76

  Albano, Laetitia ^a   Berthoux, François ^b   Moal, Marie Christine ^c   Rostaing, Lionel ^d   Legendre, Christophe ^e   Genin, Robert ^f   Toupance, Olivier ^g   Moulin, Bruno ^h   Merville, Pierre ⁱ   Rerolle, Jean Philippe ^j   Bayle, François ^k   Westeel, Pierre François ^l   Glotz, Denis ^m   Kossari, Niloufar ⁿ   Lefrançois, Nicole ^o   Charpentier, Bernard ^p,q   Blanc, Anne Sandrine ^r   Di Giambattista, Fabienne ^r   Dantal, Jacques ^s  

^a PASTEUR HOSPITAL   (France)

^b HÔPITAL NORD   (France)

^c SERVICE DE RHUMATOLOGIE   (France)

^d CHU RANGUEIL   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f Service de Néphrologie et Transplantation Rénale   (France)

^g HÔPITAL MAISON BLANCHE   (France)

^h HÔPITAL CIVIL   (France)

ⁱ HÔPITAL PELLEGRIN   (France)

^j LIMOGES UNIVERSITY HOSPITAL   (France)

^k HÔPITAL MICHALLON   (France)

^l AMIENS UNIVERSITY HOSPITAL   (France)

^m SAINT LOUIS HOSPITAL   (France)

ⁿ BICHAT HOSPITAL   (France)

^o EDOUARD HERRIOT HOSPITAL   (France)

^p BICÊTRE HOSPITAL   (France)

^q UNIVERSITÉ PARIS SACLAY   (France)

^r NOVARTIS PHARMA K K   (Japan)

^s HÔTEL DIEU   (France)

more..

Author keywords

Age; Delayed graft function; Everolimus; Kidney transplantation; MMF; Wound healing

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; ERYTHROPOIETIN; EVEROLIMUS; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; OKT 3; PREDNISONE; THYMOCYTE ANTIBODY; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ACUTE GRAFT REJECTION; ADULT; AGE; ARTERY OCCLUSION; ARTICLE; CADAVER KIDNEY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DELAYED GRAFT FUNCTION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG TOXICITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GRAFT FAILURE; HUMAN; INFECTION; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RETROPERITONEAL HEMATOMA; RISK FACTOR; SIDE EFFECT; TREATMENT OUTCOME; URINARY TRACT DISEASE; WOUND HEALING IMPAIRMENT; AGED; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; FRANCE; GRAFT REJECTION; GRAFT SURVIVAL; INCIDENCE; KIDNEY FUNCTION TEST; MIDDLE AGED; MORTALITY; TIME; TRANSPLANTATION TOLERANCE; WOUND HEALING;

AGED; DELAYED GRAFT FUNCTION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SIROLIMUS; TIME FACTORS; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME; WOUND HEALING;

EID: 67651039979     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181aa7d87     Document Type: Article

References (43)

1. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo. Transplantation 1997; 64: 36.
2. Dunn C, Croom KF. Everolimus:Areview of its use in renal and cardiac transplantation. Drugs 2006; 66: 547.
3. Schuurman HJ, Pall C, Weckbecker G, et al. SDZ RAD inhibits cold ischemia-induced vascular remodelling. Transplant Proc 1999; 31: 1024.
4. Cole OJ, Shehata M, Rigg KM. Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model. Transplant Proc 1998; 30: 2200.
5. Farb A, John M, Acampado E, et al. Oral everolimus inhibits in-stent neointimal growth. Circulation 2002; 106: 2379.
6. Nishimura T, Faul JL, Berry GJ, et al. 40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respit Crit Care Med 2001; 163: 498.
7. Waksman R, Pakala R, Baffour R, et al. Optimal dosing and duration of oral everolimus to inhibit in-stent neointimal growth in rabbit iliac arteries. Cardiovasc Revasc Med 2006; 7: 179.
8. Vitko S, Tedesco H, Eris J, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004; 4: 626.
9. Tedesco-Silva H, Vitko S, Pascual J, et al; 2306 and 2307 Study Groups. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl Int 2007; 20: 27.
10. Chan L, Greenstein S, Hardy MA, et al; CRADUS09 Study Group. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation 2008; 85: 821.
11. Nashan B, Curtis J, Ponticelli C, et al; on behalf of the 156 Study Group. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: A three-year phase II, randomized, multicenter, open-label study. Transplantation 2004; 78: 1332.
12. Sumethkul V, Changsirikulchai S, Lothuvachai T, et al. Sirolimus attenuates the rate of progression of early chronic allograft nephropathy. Transplant Proc 2006; 38: 3470.
13. Flechner SM, Kurian SM, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4: 1776.
14. Flechner SM, Goldfarb D, Solez K, et al. Kidney transplantation with sirolimus and mycophenolate mofetil based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor (CNI) drugs. Transplantation 2007; 83: 993.
15. Stallone G, Infante B, Schena A, et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005; 16: 3755.
16. Groetzner J, Kur F, Spelsberg F, et al. Airway anastomosis complications in de novo lung transplantation with sirolimus-based immuno-suppression. J Heart Lung Transplant 2004; 23: 632.
17. Neef M, Ledermann M, Saegesser H, et al. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J Hepatol 2006; 45: 786.
18. Augustine JJ, Bodziak KA, Hricik DE. Use of sirolimus in solid organ transplantation. Drugs 2007; 67: 369.
19. Bruyn GA, Tate G, Caeiro F, et al. Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: A 3-month, double-blind, randomized, placebo-controlled, parallel-group, proof-of-concept study. Ann Rheum Dis 2008; 67: 1090.
20. Reinisch W, Panés J, Lémann M, et al. Amulticenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease. Am J Gastroenterol 2008; 103: 2284.
21. Fuller TF, Freise CE, Serkova N, et al. Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion injury. Transplantation 2003; 76: 1594.
22. Lui SL, Chan KW, Tsang R, et al. Effect of rapamycin on renal ischemia-reperfusion injury in mice. Transpl Int 2006; 19: 834.
23. Lieberthal W, Fuhro R, Andry CC, et al. Rapamycin impairs recovery from acute renal failure: Role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 2001; 281: F693.
24. Durrbach A, Rostaing L, Tricot L, et al. Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor. Transplantation 2008; 85: 486.
25. Barsoum RS, Morsey AA, Iskander IR, et al. The Cairo kidney center protocol for rapamycin-based sequential immunosuppression in kidney transplant recipients: 2-year outcomes. Exp Clin Transplant 2007; 5: 649.
26. Stallone G, Di Paolo S, Schena A, et al. Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function. J Am Soc Nephrol 2004; 15: 228.
27. Boratynska M, Banasik M, Patrzalek D, et al. Impact of sirolimus treatment in kidney allograft recipients with prolonged cold ischemia times: 5-year outcomes. Exp Clin Transplant 2008; 6: 59.
28. Chang GJ, Mahanty HD, Vincenti F, et al. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function. Clin Transplant 2000; 14: 550.
29. Valente JF, Hricik D, Weigel K, et al. Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am J Transplant 2003; 3: 1128.
30. Troppmann C, Pierce JL, Gandhi MM, et al. Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: A matched-pair pilot study. Transplantation 2003; 76: 426.
31. Goel M, Flechner SM, Zhou L, et al. The influence of various maintenance immunosuppressive drugs on lymphocele formation and treatment after kidney transplantation. J Urol 2004; 171: 1788.
32. Dean PG, Lund WJ, Larson TS, et al. Wound-healing complications after kidney transplantation: A prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 2004; 77: 1555.
33. Langer RM, Kahan BD. Incidence, therapy and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients. Transplantation 2002; 74: 804.
34. Ekberg H, Tedesco-Silva H, Demirbas A, et al; for the ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
35. Kobashigawa JA, Miller LW, Russell SD, et al; Study Investigators. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006; 6: 1377.
36. Kuppahally S, Al-Khaldi A, Weisshaar D, et al. Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am J Transplant 2006; 6(5 Pt 1): 986.
37. Vitko S, Margreiter R, Weimar W, et al; for the RAD B201 Study Group. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005; 5: 2521.
38. Zuckermann A, Manito N, Epailly E, et al. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation. J Heart Lung Transplant 2008; 27: 141.
39. Margreiter R, Vitko S, Whelchel J, et al. Post-operative tissue regeneration in renal transplantation: Comparable outcome with everolimus or MMF. Transplantation 2008; 86(suppl 2): 188.
40. Pascual J. Everolimus in clinical practice - Renal transplantation. Nephrol Dial Transplant 2006; 21(suppl 3): iii18.
41. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
42. Nankivell BJ, Gruenewald SM, Allen R, et al. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995; 59: 1683.
43. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004; 43: 83.